Real-world glycemic control from GLP-1RA therapy with and without concurrent insulin in patients with type 2 diabetes

Journal of Managed Care and Specialty Pharmacy

Volumn 23, Issue 3, 2017, Pages 267-275

  Singhal, Mukul ^a   Unni, Sudhir ^a   Schauerhamer, Marisa ^a   Nguyen, Hiep ^b   Hurd, Jeff ^b   McAdam Marx, Carrie ^a  

^a UNIVERSITY OF UTAH   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; PEPTIDE; VENOM;

AGONISTS; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPOPROTEINS, LDL; LIRAGLUTIDE; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; VENOMS;

EID: 85013928085     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2017.16334     Document Type: Article

References (16)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012 Diabetes Care. 2013;36(4):1033-46.
2. Vojta D, De Sa J, Prospect T, Stevens S. Effective interventions for stemming the growing crisis of diabetes and prediabetes: a national payer's perspective. Health Aff(Millwood). 2012;31(1):20-26.
3. American Diabetes Association. 2016 standards of medical care in diabetes. Diabetes Care. 2016;39(Supplement 1):S1-2.
4. National Committee for Quality Assurance. HEDIS 2009 Volume 2 technical update. Comprehensive diabetes care. October 1, 2008. Available at: http://www.ncqa.org/portals/0/PolicyUpdates/HEDIS%20Technical%20 Updates/09_CDC_Spec.pdf. Accessed January 25, 2017.
5. Centers for Medicare & Medicaid Services. Medicare shared savings program quality measure benchmarks for the 2015 reporting year. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/MSSP-QM-Benchmarks-2015.pdf. Accessed January 16, 2017.
6. Centers for Medicare & Medicaid Services. Quality payment program. 2016 Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/MACRA-MIPSand-APMs/Quality-Payment-Program-MACRA-NPRM-Slides.pdf. Accessed January 16, 2017.
7. Garber AJ, Abrahamson MJ, Barzilay Jl, et al. AACE/ACE comprehensive diabetes management algorithm, 2015. Endocr Pract. 2015;21(4):438-47.
8. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-24.
9. Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:12.
10. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19-28.
11. Wolters Kluwer. Medi-Span Electronic Drug File (MED-File) v2 | Clinical Drug Information.
12. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234-40.
13. Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL. Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score work. Med Care. 2015;53(9):e65-72.
14. Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225-41.
15. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737-49.
16. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):e146-55.